PerkinElmer gets regulatory nod in U.S. for coronavirus test

By LabPulse.com staff writers

March 25, 2020 -- PerkinElmer is among the latest vendors to receive an emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for a reverse transcription polymerase chain reaction (RT-PCR) test for the novel coronavirus.

The agency's decision means CLIA-certified laboratories can immediately begin using the company's test kit to detect SARS-CoV-2, the virus that causes COVID-19, PerkinElmer said in a statement. The company also noted that the RT-PCR test meets the requirements of the European In Vitro Diagnostic Directive (IVDD) and is available in more than 30 countries worldwide.

PerkinElmer adjusts Q1 2020 revenue down
PerkinElmer announced that it anticipates its first quarter 2020 revenue to be lower than previously expected.
PerkinElmer, Public Health England partner on SCID test
PerkinElmer and Public Health England are collaborating on a newborn screening test for severe combined immunodeficiency (SCID), a family of rare genetic...
PerkinElmer kicks off Vanadis prenatal testing
PerkinElmer announced that it is starting to process blood samples using its Vanadis noninvasive prenatal testing system for genetic anomalies at its...
PerkinElmer CEO Robert Friel to retire
PerkinElmer executive Robert Friel is set to retire from his positions as CEO and a member of the company's board of directors, effective at the end of...
PerkinElmer touts targeted DNA test for prenatal genetic screening
PerkinElmer's Vanadis targeted cell-free DNA test had high sensitivity and specificity for finding fetal chromosomal abnormalities in high-risk pregnant...

Copyright © 2020 LabPulse.com

Last Updated np 3/25/2020 3:59:43 PM



Register below for our weekly Letter from the Editor to receive the latest Clinical Lab news and insights.
Email
Subscribe Today
Do you want to be a Microbiology Insider?

When LabPulse gets hot new information, our Insiders are the first to find out. Stay current in today's competitive market by receiving our exclusive free email updates.

Yes, Keep Me Current